GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
GI Innovation(KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy. https://mma.prnewswire.com/media/2602553/GI_____MOU.jpg This MOU was held on January 15th, local time, during JP Morgan Healthcare Conference (San Francisco, USA). The two companies have been conducting combination therapy study of the […]